Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Apr
15
Today In Oncology
Is Standard of Care Optimal for the Individual Patient?
Large Language Models May Generate Concise, Coherent Pathology Summaries, Reducing Physician Burden
PSMA PET-CT Scan Reduces Need for Prostate Cancer Biopsies
Surgery Still Safe Beneficial For Many Octogenarian Patients With NSCLC
Prompting Strategies Improve Symptom Monitoring in Childhood Cancer Survivors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo